Search

everythinglearnresearchcommunity

for

Search:↓

Diffuse hair thinning and treatments like finasteride and minoxidil. Early detection and treatment are crucial for effective management.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

OP injured their temple using derma rolling and tretinoin, causing peeling and potential hair follicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.

Intense microneedling with heavy pressure and bleeding did not improve hair growth after 4 months. The user advises against this method, noting no benefits and potential harm, and mentions using minoxidil without success.

The conversation discusses potential causes of pigmentation around hair follicles, suggesting sebum buildup, autoimmune conditions, or dermatitis. Treatments mentioned include finasteride, dutasteride, and an anti-inflammatory diet, with a recommendation to consult a doctor for a proper diagnosis.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

The conclusion of the conversation is that the user should consider using treatments such as finasteride, minoxidil, and RU58841 to potentially reverse their hair loss. Other suggestions include using hair loss concealers and maintaining a healthy diet.

The conversation discusses preventing infection from derma stamping for hair loss treatment, with suggestions to reduce needle depth and consider alternatives like tretinoin. The user experienced irritation possibly from zinc chloride and stopped using the shampoo and derma stamping.

The conversation discusses scalp itching and tenderness after microneedling, despite using medicated shampoos and proper sanitation. The user plans to see a dermatologist and is concerned about possible infection or allergic reaction.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Pyrilutamide is discussed as an effective hair loss treatment by some users, despite skepticism due to limited data and underwhelming trial results. Users compare it to finasteride, minoxidil, and RU58841, with some expressing interest in its potential as an adjunct treatment.

The user is experiencing chronic folliculitis with scalp sores and is concerned about a receding hairline. They have tried various treatments including antibiotics, Nizoral 2% shampoo, and lifestyle changes, but are seeking further advice.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

User discusses hair loss treatments, including fluridil, minoxidil, tretinoin, melatonin, stemoxydine, ketoconazole, and piroctone olamine. They suggest that shedding healthy terminal hairs may be bad, while shedding weaker hairs could indicate a beneficial treatment effect.

The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.

The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hair follicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.

The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.

The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses hair loss and the ineffectiveness of a treatment called pyrilutamide, with one user experiencing negative results and questioning the product's authenticity.

People are discussing making their own PP405 for hair loss treatment using JLX069 and DMSO. There is skepticism about the safety and effectiveness of this homemade solution, with some users expressing concerns about potential risks.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

Low-Level Laser Therapy (LLLT) for hair loss is effective but requires consistent use and device replacement every 1-2 years. The treatment is costly, and results may not be permanent without continued use.

A 17-year-old is experiencing diffuse thinning, dandruff, body hair shedding, and other symptoms, possibly linked to seborrheic dermatitis or telogen effluvium. They are using ketoconazole shampoo and considering blood tests to check for thyroid issues or deficiencies.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

The conversation discusses the struggle with diffuse hair thinning and the effectiveness of treatments like finasteride, minoxidil, and RU58841. Users share experiences of hair thickening and shedding stopping with these treatments, but results vary and some are skeptical.

A 25-year-old with AGA experienced hair thinning and dandruff, stabilized with topical finasteride and minoxidil but saw minimal regrowth. They seek advice on styling and consider oral minoxidil and microneedling for denser hair.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

The user is experiencing diffuse thinning and has tried treatments like topical and oral finasteride, oral dutasteride, topical minoxidil, microneedling, melatonin, and caffeine without success. Despite using these treatments for over four years, the user reports continued hair thinning and is considering trying RU58841.